和邦生物(603077.SH):公司雙甘膦項目會正常實施的
格隆匯6月9日丨有投資者向和邦生物(603077.SH)提問:公司擬發行可轉債46億元,轉股價3.26元,目前股價2.4元,能發行成功嗎?若上交所不批或發行不成功,公司的雙甘磷項目還會繼續嗎
和邦生物回覆:感謝您對公司的關注!公司可轉債審核進度正常,進展若達到披露標準,公司將予以披露。
“可轉債初始轉股價格不低於募集説明書公吿日前二十個交易日公司股票交易均價和前一個交易日公司股票交易均價”,公司將在可轉債獲批後根據相關規則確定轉股價格,同時也有向上、向下修正條款——請參閲募集説明書中的相關説明。
公司雙甘膦項目會正常實施的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.